FDA Approves Yeztugo as Injectable Product to Prevent HIV in Adults and Adolescents
Last week, Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir), the company’s injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrEP). Yeztugo is not labeled a “vaccine” but is a pharmaceutical product intended to reduce the risk of acquiring human immunodeficiency virus (HIV) via sexual activity […]
Novel Breast Cancer Vaccine Technology Receives Japanese Patent
Anixa Biosciences, Inc. of San Jose, California announced on July 17, 2024, that its collaborator, the Cleveland Clinic, has received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application titled “Vaccine Adjuvants and Formulations” for its novel breast cancer vaccine technology. The company is two decades into developing a […]
Adenovirus Based Coronavirus Vaccine Being Tested
Greffex, Inc., a privately-held, multinational genetic engineering company headquartered in Houston, Texas has announced that it has completed development of a vaccine for the COVID-19 coronavirus. The vaccine will now proceed to testing in laboratory animals under supervision by the U.S Food and Drug Administration (FDA) and regulatory agencies in China.1 Greffex Got $18.9M from […]